Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. genetic mutation
Show results for
Products
Services
Software
Applications

Companies

News
Articles
Books
Downloads
Videos

Refine by
Date

  • Older

Genetic Mutation Articles & Analysis

22 news found

CD Genomics Unveils Advanced Mitochondrial Diseases Panel Sequencing Service

CD Genomics Unveils Advanced Mitochondrial Diseases Panel Sequencing Service

To address this challenge, CD Genomics has developed a comprehensive Mitochondrial Diseases Panel Sequencing service that enables researchers to accurately identify mitochondrial DNA and nuclear DNA mutations and obtain a comprehensive view of the patient’s genetic makeup. ...

ByCD Genomics


CD Genomics Optimized Cancer Hotspot Panel Sequencing Service for Cancer-Related Research

CD Genomics Optimized Cancer Hotspot Panel Sequencing Service for Cancer-Related Research

Cancer is known to cause by the accumulation of harmful genetic mutations within cells. At present, the research on the mechanism of abnormal cell proliferation, differentiation, and carcinogenesis is mainly divided into three categories: activation of dominant transformation proto-oncogene through translocation and mutation, inactivation of ...

ByCD Genomics


ViGeneron presents preclinical data on intravitreal gene therapy of Stargardt disease at ESGCT

ViGeneron presents preclinical data on intravitreal gene therapy of Stargardt disease at ESGCT

[i] The most common form of the disease is caused by a genetic mutation of the ABCA4 gene, ultimately leading to vision loss. ...

ByViGeneron GmbH


CD Genomics Expands Its Sequencing Portfolio with the Launch of Whole Exome Sequencing

CD Genomics Expands Its Sequencing Portfolio with the Launch of Whole Exome Sequencing

The human genome has approximately 180,000 exomes, which are approximately 30 Mb in length, and the majority of disease-causing mutations among monogenic genetic diseases have been reported to be concentrated in the exome region. ...

ByCD Genomics


Eikonoklastes Therapeutics and Forge Biologics Announce Viral Vector Contract Development and AAV Manufacturing Partnership

Eikonoklastes Therapeutics and Forge Biologics Announce Viral Vector Contract Development and AAV Manufacturing Partnership

An estimated 10 percent of ALS is familial and caused by genetic mutations that are inherited. The 90%+ of sporadic ALS may be due to a combination of environment and genetic risk factors. ...

ByForge Biologics, Inc.


Ray Therapeutics and Forge Biologics Expand Their Viral Vector cGMP Partnership to Encompass Plasmid DNA Manufacturing

Ray Therapeutics and Forge Biologics Expand Their Viral Vector cGMP Partnership to Encompass Plasmid DNA Manufacturing

The severe loss of photoreceptor cells that occurs in this genetic degenerative disease leads to partial or complete blindness. At present, no effective treatment is available to restore vision once the photoreceptor cells have been lost. Over 100 genetic mutations are known to cause RP and all types of inheritance patterns are recognized. ...

ByForge Biologics, Inc.


Aesther Healthcare Acquisition Corp. Has Entered Into an Agreement and Plan of Merger with Ocean Biomedical, Inc., a Next-Generation Biopharma Company, to List on NASDAQ

Aesther Healthcare Acquisition Corp. Has Entered Into an Agreement and Plan of Merger with Ocean Biomedical, Inc., a Next-Generation Biopharma Company, to List on NASDAQ

Innovative Targets for Global Unmet Needs Oncology Ocean Biomedical’s novel target in oncology is Chitinase 3-Like1 (CHI3L1), a key regulator of many visceral tumors regardless of the genetic mutations that drive them. Ocean’s proprietary mono-specific and bispecific antibodies are the first to target CHI3L1. ...

ByOcean Biomedical


Emmaus Life Sciences Announces Launch of Full-Service Telehealth Solution

Emmaus Life Sciences Announces Launch of Full-Service Telehealth Solution

The sickle gene is found in every ethnic group, not just among those of African descent; and in the United States an estimated 1-in-365 African Americans and 1-in-16,300 Hispanic Americans are born with SCD.1 The genetic mutation responsible for SCD causes an individual's red blood cells to distort into a "C" or a sickle shape, reducing their ability to transport ...

ByEmmaus Medical, Inc


Vertex Advances VX-147 Into Pivotal Clinical Development for People With APOL1-Mediated Kidney Disease

Vertex Advances VX-147 Into Pivotal Clinical Development for People With APOL1-Mediated Kidney Disease

About APOL1-Mediated Kidney Disease APOL1-mediated kidney disease is a form of chronic kidney disease caused by mutations in the APOL1 gene. Approximately 100,000 people in the U.S. and Europe have two APOL1 genetic mutations and proteinuric kidney disease. People who inherit two mutations in the APOL1 gene have a course of ...

ByVertex Pharmaceuticals


Ocugen, Inc. Announces U.S. FDA Acceptance of Investigational New Drug Application to Initiate a Phase 1/2 Clinical Trial for Gene Therapy Candidate OCU400 to Treat Inherited Retinal Degeneration

Ocugen, Inc. Announces U.S. FDA Acceptance of Investigational New Drug Application to Initiate a Phase 1/2 Clinical Trial for Gene Therapy Candidate OCU400 to Treat Inherited Retinal Degeneration

Gene therapy candidate has potential to address a large number of retinitis pigmentosa and Leber congenital amaurosis gene mutations with a single product Trial to start in Q1 2022 will enroll patients with mutations in NR2E3 or RHO genes MALVERN, Pa., Dec. 09, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. ...

ByOcugen, Inc.


Transgene and NEC Announce Positive Preliminary Data From Phase I Studies of TG4050, a Novel Individualized Neoantigen Cancer Vaccine

Transgene and NEC Announce Positive Preliminary Data From Phase I Studies of TG4050, a Novel Individualized Neoantigen Cancer Vaccine

T-cell responses for each targeted mutation were assessed after 9 weeks of treatment with TG4050 and compared to baseline for the 4 patients for which evaluable samples were available. ...

ByNEC OncoImmunity AS 


Emmaus Life Sciences Announces Partnership with UpScript to Provide Telehealth Solutions to Sickle Cell Disease Patients

Emmaus Life Sciences Announces Partnership with UpScript to Provide Telehealth Solutions to Sickle Cell Disease Patients

The sickle gene is found in every ethnic group, not just among those of African descent; and in the United States an estimated 1-in-365 African Americans and 1-in-16,300 Hispanic Americans are born with SCD.1 The genetic mutation responsible for SCD causes an individual’s red blood cells to distort into a “C” or a sickle shape, reducing their ...

ByEmmaus Medical, Inc


New SARS-CoV-2 Variants II RT-PCR assay

New SARS-CoV-2 Variants II RT-PCR assay

B.1.617.2 is characterized by spike mutations T19R, G142D, Δ157-158, L452R, T478K, D614G, P681R, and D950N. ...

ByVitassay Healthcare, S.L.U.


Creative Enzymes Launches Native Porcine Prolidase for Research and Diagnostic Use

Creative Enzymes Launches Native Porcine Prolidase for Research and Diagnostic Use

Relying on its professional team and the most advanced technology, as well as high-quality products and services, it has won a good reputation all over the world Prolidase has an important role in recycling proline and collagen production. It is used to study mutations in the PEPD gene that cause prolidase deficiency. It is used to hydrolyze proteins with C-terminal proline or ...

ByCreative Enzymes


Delivering gene therapy’s promise

Delivering gene therapy’s promise

For instance, the process of generating novelty to select from cannot be precisely controlled during an experiment, but rather occurs by random genetic mutations. With this approach, the traits of interest might simply be too rare to find with random variation. ...

ByDyno Therapeutics


Eurofins Biomnis and Seqone Partner to Improve Clinical Access to Whole Exome Testing

Eurofins Biomnis and Seqone Partner to Improve Clinical Access to Whole Exome Testing

Eighty percent of rare diseases are genetic in origin and result from a small number of genetic mutations. ...

BySeqOne S.A.S.


Surgeon Explains the Importance of Preserving the Breast During Cancer Treatment through Education, the Latest Technology—and an Artistic Touch

Surgeon Explains the Importance of Preserving the Breast During Cancer Treatment through Education, the Latest Technology—and an Artistic Touch

Dr. Elizabeth Revesz has a unique background as an artist and sculptor. She was able to translate her precision, and her ability to see things in three dimensions, into a highly successful career in medicine. But once in the medical field, Dr. Revesz went further to find her true calling. “Medicine is great, but surgery is actually where I feel the most comfortable,” the physician ...

ByDilon Technologies Inc.


AB2 Bio announces readiness for recruitment in pivotal Phase 3 trial of Tadekinig alfa, a novel human recombinant interleukin-18 binding protein, in children with genetic diagnosis of NLRC4-MAS mutation or XIAP deficiency, with amended design in the U.S.

AB2 Bio announces readiness for recruitment in pivotal Phase 3 trial of Tadekinig alfa, a novel human recombinant interleukin-18 binding protein, in children with genetic diagnosis of NLRC4-MAS mutation or XIAP deficiency, with amended design in the U.S.

About the Pivotal Phase 3 Trial in Patients with Monogenic, Interleukin-18 Driven Autoinflammation due to NLRC4-MAS Mutation or XIAP Deficiency Recently, single point mutations in the NLRC4 gene have been identified. These genetic, gain of function mutations give rise to severe, life-threatening systemic inflammation associated ...

ByAB2 Bio Ltd.


NIEHS Scientists Identify the Immunity Proteins that cause a majority of DNA Damage in Several Types of Human Cancers

New research published online August 10 in the journal Nature Genetics found that a mutation-causing enzyme known at APOBEC3A (A3A) may be the main cause of mutations in certain cancers. ...

ByNational Institute of Environmental Health Sciences (NIEHS)


EPA Issues Proposed and Final HPV Test Rules; EPA Seeks Innovative Use of SNURs

EPA Issues Proposed and Final HPV Test Rules; EPA Seeks Innovative Use of SNURs

The final rule requires manufacturers and processors of 15 HPV chemical substances to conduct testing for environmental fate (including five tests for physical/chemical properties and biodegradation), ecotoxicity (in fish, Daphnia, and algae), acute toxicity, genetic toxicity (gene mutations and chromosomal aberrations), repeat dose toxicity, and developmental ...

ByBergeson & Campbell, P.C.

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT